×
About 5,773 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  1,594 results

Aortic thrombosis with visceral malperfusion during circulatory support with a combinat...
https://doi.org/10.1007/s10047-023-01382-3
Journal of Artificial Organs : the Official Journal of Th... Yamana F, Domae K et. al.

Jan 28th, 2023 - Although veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been used to aid myocardial recovery in patients with postcardiotomy cardiogenic shock (PCCS), it has been associated with adverse effects. The combined use of VA-ECMO and Im...

Evaluation Of The Effectiveness of Dantrolene Sodium against Digoxin-Induced Cardiotoxi...
https://doi.org/10.2174/1871525721666230125091826
Cardiovascular & Hematological Agents in Medicinal Chemis... Zardast M, Behmanesh K et. al.

Jan 27th, 2023 - Digoxin poisoning commonly occurs in people treated with digoxin. It has been suggested that treatment with dantrolene may be a suitable strategy for digoxin-induced cardiotoxicity. The aim of this study was to evaluate the protective effect of da...

Dietary Potassium Liberalization in Pre-Dialysis Patients
https://clinicaltrials.gov/ct2/show/NCT05090865

Jan 26th, 2023 - The kidney is a primary site of potassium regulation in the body. Hyperkalemia, elevated serum potassium, occurs in approximately 10% of patients with chronic kidney disease (CKD) and is associated with elevated all-cause mortality. To minimize th...

Potassium Disorders: Hypokalemia and Hyperkalemia.
https://www.ncbi.nlm.nih.gov/pubmed/36689973
American Family Physician; Kim MJ, Valerio C et. al.

Jan 24th, 2023 - Hypokalemia and hyperkalemia occur when serum potassium levels are less than 3.5 mEq per L or greater than 5.0 mEq per L, respectively. The World Health Organization recommends a potassium intake of at least 3,510 mg per day for optimal cardiovasc...

Type 4 renal tubular acidosis and uric acid nephrolithiasis: two faces of the same coin?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881823
Current Opinion in Nephrology and Hypertension; Adomako EA, Maalouf NM

Jan 24th, 2023 - The present review summarizes findings of recent studies examining the epidemiology, pathophysiology, and treatment of type 4 renal tubular acidosis (RTA) and uric acid nephrolithiasis, two conditions characterized by an abnormally acidic urine. B...

see more →

Guidelines  1 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

see more →

Drugs  206 results see all →

Clinicaltrials.gov  141 results

Dietary Potassium Liberalization in Pre-Dialysis Patients
https://clinicaltrials.gov/ct2/show/NCT05090865

Jan 26th, 2023 - The kidney is a primary site of potassium regulation in the body. Hyperkalemia, elevated serum potassium, occurs in approximately 10% of patients with chronic kidney disease (CKD) and is associated with elevated all-cause mortality. To minimize th...

Spironolactone for Pulmonary Arterial Hypertension
https://clinicaltrials.gov/ct2/show/NCT01712620

Jan 23rd, 2023 - INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare disorder associated with poor survival. Endothelial dysfunction resulting from 1) genetic susceptibility, and 2) a triggering stimulus that initiates pulmonary vascular injury, the two-...

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
https://clinicaltrials.gov/ct2/show/NCT04676646

Jan 23rd, 2023 - REALIZE-K is a Phase 4, multinational, multicenter, double-blind, placebo-controlled, randomized-withdrawal, parallel-group study that includes the following 3 phases: screening, 4-6 week open-label run-in phase where sodium zirconium cyclosilicat...

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
https://clinicaltrials.gov/ct2/show/NCT05348733

Jan 20th, 2023 - This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease ...

Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
https://clinicaltrials.gov/ct2/show/NCT05408039

Jan 20th, 2023 - This study is a multinational, observational, prospective, longitudinal, cohort study that will include primary and secondary data collection. Secondary data, collected as per routine clinical practice will be extracted from electronic health reco...

see more →

News  366 results

Study Sheds New Light on RAS Inhibitors' Role for Advanced CKD
https://www.medscape.com/viewarticle/983607

Nov 5th, 2022 - ORLANDO, Florida — Treatment with a renin-angiotensin system (RAS) inhibitor is widely accepted as standard practice for slowing progression of chronic kidney disease (CKD), but data have been inconsistent as to whether there is benefit to continu...

Expert calls for thoughtful approach to curbing costs in dermatology
https://www.mdedge.com/dermatology/article/258171/business-medicine/expert-calls-thoughtful-approach-curbing-costs
Doug Brunk

Sep 22nd, 2022 - PORTLAND, ORE. – About 10 years ago when Arash Mostaghimi, MD, MPA, MPH, became an attending physician at Brigham and Women’s Hospital, Boston, he noticed that some of his dermatology colleagues checked the potassium levels religiously in their fe.

Adagrasib With or Without Cetuximab Elicits Responses in Advanced KRAS G12C–Mutated CRC
https://www.onclive.com/view/adagrasib-with-or-without-cetuximab-elicits-responses-in-advanced-kras-g12c-mutated-crc

Sep 12th, 2022 - Adagrasib (MRTX849) monotherapy and in combination with cetuximab (Erbitux) generated encouraging responses in patients with advanced colorectal cancer (CRC) harboring KRAS G12C mutations, according to data from the phase 1b/2 KRYSTAL-1 trial (NCT...

Discontinuation of Allopurinol for Tumor Lysis Syndrome Report
https://www.mdedge.com/fedprac/avaho/article/257554/hematology/discontinuation-allopurinol-tumor-lysis-syndrome-report
Yasmine Ayoub, Sara Gordon et. al.

Sep 2nd, 2022 - Background/Purpose Tumor lysis syndrome (TLS) is caused by the release of intracellular products into the blood following rapid lysis of malignant cells resulting in hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Complications o.

Not Just Castleman Disease: an Elusive Diagnosis of TAFRO Syndrome
https://www.mdedge.com/fedprac/avaho/article/257528/oncology/not-just-castleman-disease-elusive-diagnosis-tafro-syndrome
Shashank Sama, Lindsey Fitzgerald et. al.

Sep 1st, 2022 - Introduction Idiopathic multicentric Castleman disease (iMCD) cases with thrombocytopenia (T), anasarca (A), Fever (F), reticulin fibrosis (R), and organomegaly (O) are considered a subtype of iMCS called TAFRO syndrome. It is a rare syndrome char.

see more →

Patient Education  1 results see all →